[Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
BACKGROUND
Behçet's disease (BD) is a systemic vasculitis of unknown origin. Up to now ocular involvement has a poor visual prognosis irrespective of immunosuppressive treatment. Now recent open studies have shown that interferon alfa-2a (IFN alfa-2a) is very effective in the treatment of ocular BD. The purpose of this study was to evaluate the long-term development of visual acuity (VA) in patients with severe ocular BD who were treated with IFN alfa-2a.


METHODS
We included 15 eyes of 9 patients with an active panuveitis and/or retinal vasculitis due to BD refractory to immunosuppressive treatment. VA before initiation of IFN-therapy was compared to VA at the end of the follow-up time.


RESULTS
Mean follow-up time was 68.8+/-10.6 months. Mean duration of IFN-treatment was 40.6+/-17.0 months. With the exception of one patient IFN alfa-2a could be discontinued in complete remission of ocular symptoms. During the follow-up time 10 eyes showed an increase of VA of two lines or more. In 5 eyes VA remained stable. There was no decrease of VA in any eye. If a macular edema was present, a quick response to IFN alfa-2a was seen. No eye developed a pale optic disk during follow-up.


CONCLUSIONS
Compared to conventional immunosuppressants, interferon alfa-2a seems to be much more effective to prevent a loss or decrease of VA over a long period of time in patients with severe ocular BD.
Deuter
C M E
CM
Abteilung I-Erkrankungen des vorderen und hinteren Augenabschnittes, Universitäts-Augenklinik, Tuebingen. christoph.deuter@med.uni-tuebingen.de
Kötter
I
I
Günaydin
I
I
Zierhut
M
M
Stübiger
N
N
D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D015864:Panuveitis / Q000188:drug therapy*; D011379:Prognosis; D011994:Recombinant Proteins; D031300:Retinal Vasculitis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins